Cancer patient in Wales denied life-extending drug
A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...
New blood test offers early detection of drug-induced tissue damage in cancer patients
A team of researchers have applied a novel blood test that can detect early signs of potentially fatal lung damage in cancer ...
News Medical3d
New blood test detects early lung damage in cancer patients on targeted therapy
In this study, researchers retrospectively examined blood from patients with metastatic HER2-positive cancers who were ...
Pharmabiz4d
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product
Daiichi Sankyo & AstraZeneca’s Enhertu receives 2024 Prix Galien USA Award for Best Biotechnology Product: Tokyo Monday, November 11, 2024, 09:00 Hrs [IST] Daiichi Sankyo and As ...
Targeted Oncology4d
The Targeted Pulse: A Review of Last Month’s FDA Prominent Actions and Key Data Updates Advancing Treatment Across Disease Types
Some of the major updates include the approval of acalabrutinib (Calquence) for first-line treatment of mantle cell lymphoma, the FDA’s priority review of fam-trastuzumab deruxtecan-nxki (T-DXd; ...
pharmaphorum6d
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous ...